Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
about
Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agentPharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects.Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review.Aortocaval fistula in rat: a unique model of volume-overload congestive heart failure and cardiac hypertrophy.How does zinc supplementation benefit anorexia nervosa?Natriuretic peptide pharmacogenetics: membrane metallo-endopeptidase (MME): common gene sequence variation, functional characterization and degradation.Recent advances in natriuretic peptide researchCombination of drugs acting on the natriuretic system and the renin-angiotensin system in heart failure.Dilating the degradome: matrix metalloproteinase 2 (MMP-2) cuts to the heart of the matter.Reciprocal regulation of human soluble and particulate guanylate cyclases in vivo.Utilizing imaging tools in lipidology: examining the potential of MRI for monitoring cholesterol therapy.Vasoactive peptides in cardiovascular (patho)physiology.C-Type Natriuretic Peptide Improves Left Ventricular Functional Performance at Rest and Restores Normal Exercise Responses after Heart Failure.Atherosclerosis monitoring in the elderly using magnetic resonance imaging: is the extra step needed?Neprilysin null mice develop exaggerated pulmonary vascular remodeling in response to chronic hypoxiaNatriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases.Dietary zinc intake is inversely associated with systolic blood pressure in young obese womenIntraperitoneal fat is associated with thickening of the thoracic aorta in individuals at high risk for cardiovascular eventsHigher natriuretic peptide levels associate with a favorable adipose tissue distribution profile.Natriuretic peptides and cardiovascular damage in the metabolic syndrome: molecular mechanisms and clinical implications.Combined neutral endopeptidase inhibitors.Targeting the renin-angiotensin-aldosterone system in heart failure.Lost in translation: five grand challenges for proteomic biomarker discovery.Natriuretic peptides in cardiovascular diseases: current use and perspectivesNovel blockers of the renin-angiotensin-aldosterone system in chronic heart failure.Modulation of the renin-angiotensin-aldosterone system in heart failure.Are there any new pharmacologic therapies on the horizon to better treat hypertension? A state-of-the-art paper.New developments in the pharmacological treatment of hypertension: dead-end or a glimmer at the horizon?The multifaceted role of natriuretic peptides in metabolic syndrome.Impact of statins on atherosclerotic plaque.Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator.Neprilysin, obesity and the metabolic syndromeComment on: Cherney and Sochett. Evolution of renal hyperfiltration and arterial stiffness from adolescence into early adulthood in type 1 diabetes. Diabetes Care 2011;34:1821-1826.Biochemical analysis of neutral endopeptidase activity reveals independent catabolism of atrial and brain natriuretic peptide.Response to Comment on: Cherney and Sochett. Evolution of Renal Hyperfiltration and Arterial Stiffness From Adolescence Into Early Adulthood in Type 1 Diabetes. Diabetes Care 2011;34:1821–1826.Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis.Moderate zinc deficiency influences arterial blood pressure and vascular nitric oxide pathway in growing rats.Increased natriuretic peptide receptor A and C gene expression in rats with pressure-overload cardiac hypertrophy.Imaging biomarkers of atherosclerosis.Cardiorenal protection in experimental hypertension with renal failure: comparison between vasopeptidase inhibition and angiotensin receptor blockade.
P2860
Q33573360-625721EA-D72D-43A0-8F09-1D0C1C50E2FFQ34229717-23F87FA9-706E-4835-A9F9-FD668C86D1FFQ34495751-AC1315B9-B1C2-4CDC-AD93-1EBD16A3438DQ34512883-324DDE8F-4227-4739-BC48-3EFB7EC8D262Q34608804-62FD3E15-C2EC-44F2-8A49-2C3C03701A5FQ34971920-89FC9A0D-86D7-4503-8C16-175AAD5A81C1Q35459776-6C90B38D-DE01-4382-AE67-74CA70A951FAQ35580130-5E5A01DF-DE68-4EED-8D66-B0D6A31A2E2FQ35929334-58BE71D6-D85D-49DE-B7A2-22C66BFA73F6Q36054367-7E54C7FB-BF75-4D47-AA47-D7740DFF1B5AQ36422755-6764B881-63C2-4079-8A23-4B3161A02984Q36815987-967203E0-C970-4CDA-9F6F-DB671997DDA2Q36947760-141F0343-EB24-49DB-8F44-82144131E212Q36987734-526026E2-DA20-43E9-9F60-F8FD50AAF732Q37150753-0993A7EC-4C94-43D4-855B-A3088EE76472Q37157505-A56F3368-4C66-461C-943C-92AA1AF6F27FQ37229825-19584FFD-7AF4-4AE3-A73C-69C1FEA5D31AQ37270637-AC34438A-0A2B-4C56-BFCB-1F0D6371C80EQ37378648-2C076E17-A391-44D1-A6C5-D5595C54AB80Q37626852-C6B3435C-99D7-4FEA-B2E0-1B227ADE5499Q37842465-7EDB711B-8DC5-47B3-BA64-67019F0E2940Q38074092-738AAB60-1F1C-483E-8B3C-9DA8367006C4Q38089257-44E7E024-273E-48F3-A93A-0CABDE14EEE4Q38162429-799DC0C2-EF8A-442F-A84F-5130A4CA8BE6Q38162791-EC301C07-F564-4EEC-A03F-8E1B4D3DD16FQ38186633-861FA113-EACA-47F7-B4A5-46B48B780977Q38208808-6815D18C-1082-4C37-BA28-5B8786BBB45DQ38429870-8266363D-CE5A-4B69-80CC-FA69E62ABAE2Q39362608-127C21CF-FD87-44E3-ACDB-BD3BC39AA0E1Q40238908-EB11B9A4-3C30-4957-A208-DD6F23331287Q40526206-76CE7236-21FB-4606-88B4-BEE63F648972Q42610866-DA696D0F-2EFC-4371-BE1B-18490A7067E3Q42974588-41CC673F-C01F-467F-9251-858B38E89870Q44854138-7A83A892-579D-48FD-88C8-49097CDD256BQ45905267-B1A398A5-8CD3-4871-B85E-297E11B902B1Q46708648-CC545E9F-54DF-4510-8B7D-E6166FBE7200Q46724442-83CBCACE-7302-4AE2-9134-A65C9AD02D16Q46792345-B2F42A2A-4005-4563-9245-A2B88B0DD1CBQ51945900-8E411BDB-153A-4F83-B6AF-331CB6BF7640Q52878009-C02FF862-8D7F-4266-91E2-29D5D0D901A5
P2860
Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
@ast
Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
@en
Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
@nl
type
label
Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
@ast
Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
@en
Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
@nl
prefLabel
Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
@ast
Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
@en
Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
@nl
P2093
P356
P1433
P1476
Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
@en
P2093
Burnett JC Jr
Lüscher TF
Rouleau JL
Ruschitzka F
P304
P356
10.1161/HC4001.097191
P407
P577
2001-10-01T00:00:00Z